Viridian Therapeutics Inc (VRDN)

07:32 AM

Propel Bio Management LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat

07:32 AM

Mar 04, 2026

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment By Investing.com - Investing.com South Africa

Mar 04, 2026

Mar 04, 2026

Viridian Therapeutics at TD Cowen Conference: Strategic Moves in TED Treatment - Investing.com Australia

Mar 04, 2026

Mar 04, 2026

[144] Viridian Therapeutics, Inc.DE SEC Filing - Stock Titan

Mar 04, 2026

Mar 04, 2026

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com

Mar 04, 2026

Mar 04, 2026

Viridian Therapeutics, Inc. $VRDN Position Increased by Fisher Asset Management LLC - MarketBeat

Mar 04, 2026

Mar 03, 2026

Viridian Therapeutics, Inc. (VRDN): Investor Outlook on a Biotech Powerhouse with 38% Upside Potential - DirectorsTalk Interviews

Mar 03, 2026

Mar 01, 2026

Viridian Therapeutics (VRDN) Balances Rising Losses With Veligrotug Milestones and New Employee Stock Shelf Registration - Sahm

Mar 01, 2026

Feb 28, 2026

What analyst consensus says on Viridian Therapeutics Inc. stockRisk Management & Free Growth Oriented Trading Recommendations - mfd.ru

Feb 28, 2026

Feb 27, 2026

How (VRDN) Movements Inform Risk Allocation Models - Stock Traders Daily

Feb 27, 2026

Feb 27, 2026

Royal Bank Of Canada Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat

Feb 27, 2026

Feb 27, 2026

Viridian Therapeutics (VRDN) Analyst Maintains Rating; Adjusts P - GuruFocus

Feb 27, 2026

Feb 27, 2026

RBC Adjusts Price Target on Viridian Therapeutics to $42 From $45, Maintains Outperform Rating - marketscreener.com

Feb 27, 2026

Feb 27, 2026

What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders - Yahoo Finance

Feb 27, 2026

Feb 27, 2026

VRDN Should I Buy - Intellectia AI

Feb 27, 2026

Feb 27, 2026

Decoding Viridian Therapeutics Inc (VRDN): A Strategic SWOT Insi - GuruFocus

Feb 27, 2026

Feb 27, 2026

Jefferies Maintains Buy, PT $45 for Viridian Therapeutics (VRDN) Feb 2026 - Meyka

Feb 27, 2026

Feb 26, 2026

VRDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics (NASDAQ:VRDN) Releases Earnings Results, Misses Expectations By $0.18 EPS - MarketBeat

Feb 26, 2026

Feb 26, 2026

Jefferies raises Viridian Therapeutic stock price target on trial progress By Investing.com - Investing.com Canada

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 26, 2026

Feb 26, 2026

Wedbush Cuts Viridian Therapeutics Price Target to $44 From $47, Maintains Outperform Rating - marketscreener.com

Feb 26, 2026

Feb 26, 2026

Evercore ISI reiterates Viridian Therapeutic stock rating on data conviction By Investing.com - Investing.com Canada

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics earnings beat by $0.64, revenue topped estimates - Investing.com

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics earnings missed by $0.10, revenue fell short of estimates - Investing.com UK

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics Q4 revenue misses analyst expectations - TradingView

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics Reports Q4 and Full Year 2025 Financial Results - TradingView

Feb 26, 2026

Feb 26, 2026

TED drug veligrotug nears FDA decision as Viridian (NASDAQ: VRDN) ramps spend - Stock Titan

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire

Feb 26, 2026

Feb 26, 2026

Viridian Therapeutics (VRDN) TTM US$342.6 Million Loss Tests Bullish Growth Narratives - Sahm

Feb 26, 2026

Feb 26, 2026

Tech Rally: What is the implied volatility of Viridian Therapeutics IncTrade Exit Report & AI Optimized Trade Strategies - baoquankhu1.vn

Feb 26, 2026

Feb 26, 2026

Growth Review: Is Viridian Therapeutics Inc subject to activist investor interest2025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn

Feb 26, 2026

Feb 25, 2026

VRDN PE Ratio & Valuation, Is VRDN Overvalued - Intellectia AI

Feb 25, 2026

Feb 23, 2026

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - The Motley Fool

Feb 23, 2026

Feb 22, 2026

Can Viridian Therapeutics Inc. stock double in the next year2025 Key Highlights & Real-Time Chart Breakout Alerts - mfd.ru

Feb 22, 2026

Feb 20, 2026

Can Viridian Therapeutics Inc. be the next market leader2025 Valuation Update & Long Hold Capital Preservation Plans - mfd.ru

Feb 20, 2026

Feb 20, 2026

Is Viridian Therapeutics Inc.’s ROIC above industry averageWeekly Risk Report & Free Community Supported Trade Ideas - mfd.ru

Feb 20, 2026

Feb 20, 2026

Viridian Preparing To Launch Its First Drug And A Fast Follower In TED - Citeline News & Insights

Feb 20, 2026

Feb 20, 2026

VRDN SEC FilingsViridian Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 20, 2026

Feb 19, 2026

What are Viridian Therapeutics Inc.’s earnings expectations2025 Valuation Update & Free Expert Approved Momentum Trade Ideas - mfd.ru

Feb 19, 2026

Feb 19, 2026

Viridian Therapeutics (VRDN) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Feb 19, 2026

Feb 18, 2026

Viridian Therapeutics surveys impact of thyroid eye disease on daily life - Traders Union

Feb 18, 2026

Feb 18, 2026

Truist reiterates Viridian Therapeutic stock rating ahead of trial By Investing.com - Investing.com Canada

Feb 18, 2026

Feb 17, 2026

Viridian Therapeutics, Inc. (VRDN) Stock Analysis: A 50.75% Upside Potential In Biotech - DirectorsTalk Interviews

Feb 17, 2026

Feb 17, 2026

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 17, 2026

Feb 16, 2026

Trading Systems Reacting to (VRDN) Volatility - Stock Traders Daily

Feb 16, 2026

Feb 13, 2026

Published on: 2026-02-13 20:43:42 - mfd.ru

Feb 13, 2026

Feb 12, 2026

What is the implied volatility of Viridian Therapeutics Inc.Weekly Investment Recap & Risk Managed Investment Strategies - mfd.ru

Feb 12, 2026

Feb 10, 2026

Viridian Therapeutics, Inc. (VRDN) Stock Analysis: 42% Potential Upside Amidst Breakthrough Biotechnology Advances - DirectorsTalk Interviews

Feb 10, 2026

Feb 09, 2026

Street Watch: What are the future prospects of Viridian Therapeutics IncJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Feb 09, 2026

Feb 06, 2026

How Viridian Therapeutics Inc. (VRDN) Affects Rotational Strategy Timing - Stock Traders Daily

Feb 06, 2026

Feb 05, 2026

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail

Feb 05, 2026

Feb 04, 2026

Viridian Therapeutics' (VRDN) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Feb 04, 2026

Feb 04, 2026

VRDN: Needham Reiterates Buy Rating with Maintained Price Target | VRDN Stock News - GuruFocus

Feb 04, 2026

Feb 03, 2026

Performance Recap: Can Alerus Financial Corporation stock outperform in a bear marketMarket Trend Report & Verified Technical Signals - baoquankhu1.vn

Feb 03, 2026

Feb 03, 2026

Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN) and Enovis (ENOV) - The Globe and Mail

Feb 03, 2026

Feb 03, 2026

Viridian Therapeutics (VRDN) Receives Updated Analyst Rating fro - GuruFocus

Feb 03, 2026

Feb 03, 2026

Wells Fargo & Company Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock - MarketBeat

Feb 03, 2026